1. Draw 0.5 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to avoid foaming; do not shake.
3. Gently swirl or roll the vial until the powder is completely dissolved.
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light.
5. Use within 7 days of reconstitution for optimal potency. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

GHRP-6 functions as a synthetic ghrelin mimetic by binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary gland and hypothalamus. This activation triggers acute, pulsatile growth hormone release from somatotroph cells while simultaneously reducing somatostatin’s inhibitory brake on GH secretion. Unlike continuous GH administration, GHRP-6 maintains physiological feedback controls: as GH and IGF-1 levels rise, endogenous somatostatin increases to prevent excessive elevation, keeping GH pulses within normal physiologic ranges. Beyond its endocrine effects, GHRP-6 exhibits cytoprotective properties through interactions with the CD36 receptor on immune and muscle cells. This secondary pathway activates cell-survival signaling cascades (such as PI3K/Akt) that help protect tissues from oxidative stress and inflammation, explaining many of GHRP-6’s observed tissue-protective benefits in preclinical models including

• Muscle Growth & Fat Loss: Elevated GH and IGF-1 levels support increased lean body mass and
  reduced fat mass over time.
• Enhanced Recovery: Improved sleep architecture (increased slow-wave sleep) and faster tissue repair. Appetite Stimulation: May increase hunger due to ghrelin receptor activation, potentially beneficial for weight gain goals.
• Tissue Protection: Preclinical studies show cytoprotective effects including reduced scar formation,
  cardioprotection, and neuroprotection.
• Joint & Connective Tissue Health: May support collagen synthesis and connective tissue repair
  through elevated IGF-1.
• Transient mild increases in cortisol and ACTH (typically not clinically significant).
  Increased appetite and potential water retention.
• Occasional injection-site reactions (redness, itching, mild swelling).
• Possible transient dizziness or flushed feeling immediately after injection due to rapid GH spike.
• Generally well-tolerated in human trials at research doses with no major safety concerns reported.